NCT03894618 · REGISTRY CONDITION SEARCH

SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE1
Status at capture: COMPLETED
Registry last update: 2025-04-02

This is a Phase 1 first in human, open label, multi-center, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, anti-tumor activity and pharmacodynamic effects of SL-279252 in subjects with advanced solid tumors or lymphomas.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Safety Profile of SL-279252

→

outcome · POSTED

Maximum Tolerated Dose (MTD) of SL-279252

→

outcome · POSTED

Recommended Phase 2 Dose for SL-279252

→

outcome · POSTED

Overall Response Rate of SL-279252

→

outcome · POSTED

Immunogenicity to SL-279252

→

outcome · POSTED

Maximum Serum Concentration (Cmax) of SL-279252

→

outcome · POSTED

Minimum Serum Concentration (Cmin) of SL-279252

→

outcome · POSTED

Time at Which Maximum Concentration of SL-279252 is Observed (Tmax)

→

outcome · POSTED

Area Under the Serum Concentration-time Curve (AUC)

→

outcome · POSTED

Terminal Half Life (t1/2)

→

outcome · POSTED

Clearance

→

outcome · POSTED

Volume of Distribution

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: Participants are eligible to be included in the study only if all the following criteria apply. 1. Subject has voluntarily agreed to participate by giving written informed consent in accordance with ICH/GCP guidelines and applicable local regulations. 2. Subject has a histologically confirmed diagnosis of one of the following unresectable locally advanced or metastatic malignancies: melanoma, non-small cell lung cancer (squamous, adeno, or adeno-squamous), urothelial cancer, squamous cell carcinoma of the head and neck, squamous cell cervical cancer, gastric or gastro-esophageal junction adenocarcinoma, squamous cell carcinoma of the anal canal, squamous cell carcinoma of the skin, renal cell cancer, Hodgkin's lymphoma, and microsatellite instability high (MSI-H) or mismatch repair deficient (MMRD) solid tumors excluding CNS malignancies. MSI and MMRD testing results as per institution is acceptable. * Head and neck cancers: Subjects must have primary tumor locations in the oropharynx, oral cavity, hypopharynx, or larynx. Primary tumor sites of nasopharynx, maxillary sinus, paranasal, and unknown primary are excluded. * Non-small cell lung cancers: Subjects with a known EGFR sensitizing (activating) mutation or an ALK fusion are excluded. 3. Subject must have received, been intolerant to, or is ineligible for standard therapy (per local guidelines and approvals) or have a malignancy for which there is no approved therapy considered standard of care. 4. Age 18 years and older. 5. Has an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1. 6. Has measurable disease by iRECIST (solid tumors) or RECIL 2017 (lymphoma). Refer to Appendix Sections 16.6 and 16.7 for details on criteria of measurable disease. 7. Has life expectancy of greater than 12 weeks. 8. Laboratory values must meet the following criteria. Laboratory parameter Threshold value * Absolute lymphocyte count (ALC) ≥ 0.8 x 109/liter (L) * Absolute neutrophil count (ANC) ≥ 1.5 x 109/L without growth factor support * Platelet count ≥ 50 x 109/L Laboratory parameter Threshold value * Hemoglobin (Hgb) \> 9.0 g/dL with no blood transfusions for at least 5 days prior to D1 of investigational product (IP; SL-279252) * Creatinine clearance (CrCl) ≥ 30 milliliter (mL)/min (modified Cockcroft-Gault) * ALT/AST ≤ 3 x ULN * Total bilirubin ≤ 1.5 x ULN; subjects with isolated indirect hyperbilirubinemia are permitted if direct bilirubin ratio is \<35% and total bilirubin is ≤ 3.0 x ULN * Left ventricular ejection fraction (LVEF) by echocardiogram (ECHO) ≥ lower limit of normal (LLN) per institutional threshold. If LLN is not defined for a given institution, then ejection fraction must be ≥50 %. 9. Females of child bearing potential (FCBP) must have a negative serum or urine pregnancy test within 72 hours of D1 of IP. NOTE: FCBP unless they are surgically sterile (i.e., have undergone a complete hysterectomy, bilateral tubal ligation/occlusion, bilateral oophorectomy or bilateral salpingectomy), have a congenital or acquired condition that prevents childbearing or are naturally postmenopausal for at least 12 consecutive months (see Appendix Section 16.2 for additional details). Documentation of postmenopausal status must be provided. FCBP should use an acceptable method of contraception (see Appendix Section 16.2) to avoid pregnancy during treatment and for 30 days (which exceeds 5 half-lives) after the last dose of IP. FCBP must start using acceptable contraception at least 14 days prior to D1 of IP. 10. Male subjects with female partners must have azoospermia from a prior vasectomy or underlying medical condition or agree to use an acceptable method of contraception during treatment and for 30 days (which exceeds 5 half-lives) after last dose of SL-279252 (see Appendix Section 16.2). Male subjects of reproductive potential must start using acceptable contraception at least 14 days prior to D1 of treatment with SL-279252 as per Appendix Section 16.2. 11. All AEs resulting from prior anti-cancer immunotherapy have resolved (NOTE: exceptions include alopecia, vitiligo, and endocrinopathies adequately treated with hormone replacement). • Subjects that were discontinued from prior PD-1/L1 therapy due to immune-related adverse events are not eligible 12. Recovery from toxicities from prior anti-cancer treatments including surgery, radiotherapy, chemotherapy or any other anti-cancer therapy to baseline or ≤ Grade 1. (NOTE: Low-grade toxicities (e.g., alopecia, ≤ Grade 2 lymphopenia, ≤ Grade 2 hypomagnesemia, ≤ Grade 2 neuropathy) may be allowed at the discretion of the investigator if considered clinically insignificant. Please consult the Sponsor Medical Monitor to discuss these cases). Exclusion Criteria: Participants are excluded from the study if any of the following criteria apply: 1. Has received more than two prior checkpoint inhibitor containing treatment regimens (regimen refers to either monotherapy or combination immunotherapies) or has had prior treatment with an OX40 agonist. • Prior PD-1/L1 therapy is not required. 2. Refractory to last PD-1/L1 inhibitor-based therapy which is defined as disease progression within 3 months of treatment initiation. • Subjects must have had clinical benefit (stable disease or response) to last PD-1/L1 inhibitor-based therapy for at least three months to be eligible. 3. Any anti-cancer therapy within the time intervals noted below prior to first dose (D1) of SL-279252. Therapy Washout period Chemotherapy 3 weeks Hormonal therapy 3 weeks PD-1/L1 inhibitor and other immunotherapies not otherwise specified 3 weeks Tumor vaccine 4 weeks Cell-based therapy 8 weeks Other mAbs or biologic therapies 3 weeks Major surgery 2 weeks Radiation (except palliative intent which does not require washout) 2 weeks 4. Concurrent chemotherapy, immunotherapy, biologic or hormonal therapy is prohibited. Concurrent use of hormones for non-cancer related conditions is acceptable. 5. Use of corticosteroids or other immunosuppressive medication, current or within 14 days of D1 of IP with the following exceptions (i.e., the following are allowed during treatment with or within14 days of D1 of IP): * Topical, intranasal, inhaled, ocular, intraarticular corticosteroids * Physiological doses of replacement steroid (e.g., for adrenal insufficiency) provided ≤ 10 mg/day of prednisone or equivalent * Steroid premedication for hypersensitivity reactions (HSRs; e.g., reaction to IV contrast) 6. Receipt of live attenuated vaccine within 28 days of D1 of IP. 7. Active or documented history of autoimmune disease (autoimmune disease does not refer to irAEs; for irAEs see inclusion criteria #11). Exceptions include Type I diabetes, vitiligo, alopecia areata or hypo/hyperthyroidism. 8. Active pneumonitis (i.e. drug-induced, idiopathic pulmonary fibrosis, radiation-induced, etc.). 9. Ongoing or active infection (e.g., no systemic antimicrobial therapy for treatment of infection within 5 days of D1 of IP). 10. Symptomatic peptic ulcer disease or gastritis, active diverticulitis, other serious gastrointestinal (GI) disease associated with diarrhea within 6 months of D1 of IP. 11. Clinically significant or uncontrolled cardiac disease including any of the following: * Myocarditis * Unstable angina within 6 months from D1 of IP * Acute myocardial infarction within 6 months from D1 of IP * Uncontrolled hypertension * New York Heart Association (NYHA) Class II, III or IV congestive heart failure * Clinically significant (symptomatic) cardiac arrhythmias (e.g., sustained ventricular tachycardia, second- or third- degree atrioventricular block without a pacemaker, circulatory collapse requiring vasopressor or inotropic support, or arrhythmia requiring therapy) 12. Untreated central nervous system (CNS) or leptomeningeal metastases. Subjects with treated CNS metastases must have completed definitive treatment (radiotherapy and/or surgery) \> 2 weeks prior to D1 of IP and no longer require steroids. 13. Women who are breast feeding. 14. Psychiatric illness/social circumstances that would limit compliance with study requirements and substantially increase the risk of AEs or compromised ability to provide written informed consent. 15. Another malignancy that requires active therapy and that in the opinion of the investigator and Sponsor would interfere with monitoring of radiologic assessments of response to IP. 16. Has undergone allogeneic stem cell transplantation or organ transplantation. 17. Known history or positive test for human immunodeficiency virus, or positive test for hepatitis B (positive for hepatitis B surface antigen \[HBsAg\]) or hepatitis C virus (\[HCV\]; if HCV antibody (Ab) test is positive check for HCV ribonucleic acid \[RNA\]). * (NOTE: Hepatitis B virus (HBV): Subjects who are hepatitis B core antibody \[HBcAb\] positive, but HBsAg negative are eligible for enrollment. HCV: Subjects who are HCV Ab positive, but HCV RNA negative are eligible for enrollment).
healthy Volunteers: false
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Intravenous administration; Two possible dosing schedules for SL-279252 may be evaluated
intervention Names
Drug: SL-279252
label
SL-279252
type
EXPERIMENTAL

interventions

arm Group Labels
SL-279252
description
The investigational product (IP), SL-279252, is a first-in-class agonist redirected checkpoint (ARC) fusion protein (FP) consisting of the extracellular domains of human programmed cell death 1 (PD- 1) and OX40L, linked by a central Fc domain (PD1-Fc-OX40L).
name
SL-279252
type
DRUG

Study design

allocation

intervention Model

SEQUENTIAL

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 49
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Number of participants with treatment emergent adverse events
measure
Safety Profile of SL-279252
time Frame
From Day 1 to 90 days after Last Dose of SL-279252
description
Number of participants with dose limiting toxicities (DLTs)
measure
Maximum Tolerated Dose (MTD) of SL-279252
time Frame
From Day 1 to Day 21 (Schedule 1) or Day 28 (Schedule 2)

secondary Outcomes

description
Based on review of all data, including safety, tolerability, PK, antitumor activity, and PD effects
measure
Recommended Phase 2 Dose for SL-279252
time Frame
Approximately 32 months
description
Objective response rate per immune response evaluation criteria in solid tumors (iRECIST) for solid tumors
measure
Overall Response Rate of SL-279252
time Frame
Approximately 32 months
description
Number of participants with positive anti-drug antibody (ADA) titer, of those who were ADA negative at baseline
measure
Immunogenicity to SL-279252
time Frame
Approximately 32 months
description
The Cmax is the maximum observed serum concentration of SL-279252 following single and multiple doses
measure
Maximum Serum Concentration (Cmax) of SL-279252
time Frame
Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 1 (cycle = 28 days)
description
The Cmin is the minimum observed serum concentration of SL-279252 following single and multiple doses
measure
Minimum Serum Concentration (Cmin) of SL-279252
time Frame
Cycle 1 Day 15 and Cycle 2 Day 1 (cycle = 28 days)
description
The Tmax is the time at which the maximum concentration of SL-279252 is observed following single and multiple doses
measure
Time at Which Maximum Concentration of SL-279252 is Observed (Tmax)
time Frame
Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 1 (cycle = 28 days)
description
The AUC is the area under the serum concentration time curve following single and multiple doses of SL-279252. AUC (0-inf; from time 0 to infinity) is reported for C1D1 and C2D1 (Schedule 1 only); AUC (tau; over a dosing interval) is reported for C1D15 and C2D1 (Schedule 2 only).
measure
Area Under the Serum Concentration-time Curve (AUC)
time Frame
Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 1 (cycle = 28 days)
description
The t1/2 elimination half-life of SL-279252
measure
Terminal Half Life (t1/2)
time Frame
Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 1 (cycle = 28 days)
description
Clearance of SL-279252
measure
Clearance
time Frame
Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 1 (cycle = 28 days)
description
Volume of distribution of SL-279252
measure
Volume of Distribution
time Frame
Cycle 1 Day 1, Cycle 1 Day 15, and Cycle 2 Day 1 (cycle = 28 days)

Full study description

brief Summary: This is a Phase 1 first in human, open label, multi-center, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, anti-tumor activity and pharmacodynamic effects of SL-279252 in subjects with advanced solid tumors or lymphomas.
detailed Description: This is a Phase 1 first in human, open label, multi-center, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, anti-tumor activity and pharmacodynamic effects of SL-279252 in subjects with advanced solid tumors or lymphomas. The study design consists of Dose Escalation and Dose Expansion Cohorts. In the dose escalation phase of the study, subjects will be enrolled into sequential dose levels. During dose escalation, two possible schedules for administration of SL-279252 may be explored. The MTD or MAD may be determined for either schedule. Based on accumulating data from the dose escalation phase, including safety, PK, pharmacodynamic and anti-tumor activity, up to two dose expansion cohorts may be opened. The primary objective of the expansion phase is to further refine the safety and tolerability of SL-279252. The expansion cohorts will evaluate one or two doses of SL-279252 using one selected schedule. At the end of dose escalation and dose expansion, safety, PK, anti-tumor activity, and pharmacodynamic data will be reviewed to identify the RP2D.

Source references

references

citation
Johnson M, Hong D, Brana I, Schoffski P, Galvao V, Rangwala F, Ma B, Hernandez R, Kamat A, Kato K, Schreiber TH, Pandite L, Siu LL. First-in-human, phase 1 dose escalation study of SL-279252, a hexameric PD1-Fc-OX40L fusion protein, in patients with advanced solid tumors and lymphoma. Invest New Drugs. 2025 Apr;43(2):284-292. doi: 10.1007/s10637-025-01518-7. Epub 2025 Mar 5.
pmid
40042547
type
DERIVED

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-b7fdfacb3ca338cb3af4
requested nct id
NCT03894618
primary nct id
NCT03894618
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Small+Intestine+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
69c40ed34b17434f684079ec5635264bc5ad292871a86b835704fc99fa9d8157
payload sha256
2ea8ff6cfb18afc0127d93d9845ce9ab058b9c84a526c565bf8536499c6f6d52
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-b7fdfacb3ca338cb3af4
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT03894618
occurrences
context exact
NCT03894618
end
11
exact text
NCT03894618
start
0
offset unit
unicode_code_points
query cond
Small Intestine Cancer
query disease state id
ds-small-intestine-cancer
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-small-intestine-cancer-000.json
source file sha256
69c40ed34b17434f684079ec5635264bc5ad292871a86b835704fc99fa9d8157
source json pointer
/studies/14/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
1f2f9ae0c10e649a859b83ff32ea5f3b639f5ea1b66c0bc33408ba395a97ab0c
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Small+Intestine+Cancer&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice